Benzinga | Nov 9, 2021 11:36AM EST

Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.40) by 20.42 percent. This is a 28.46 percent increase over losses of $(2.67) per share from the same period last year. The company reported quarterly sales of $135.74 million which beat the analyst consensus estimate of $128.40 million by 5.72 percent. This is a 668.46 percent increase over sales of $17.66 million the same period last year.